journal
https://read.qxmd.com/read/37431233/revolutionizing-hepatocellular-carcinoma-treatment-the-advent-of-a-new-era-of-adjuvant-therapy
#21
JOURNAL ARTICLE
Joshua Sheng Hao Lim, Vishal G Shelat
No abstract text is available yet for this article.
June 28, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37355810/when-not-having-a-tissue-may-not-be-an-issue-in-advanced-lung-cancer
#22
JOURNAL ARTICLE
Shenduo Li, Yanyan Lou, Rami Manochakian
No abstract text is available yet for this article.
June 20, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37303222/is-there-a-role-for-first-generation-tkis-in-adjuvant-setting-of-egfr-mutated-early-nsclc
#23
JOURNAL ARTICLE
Aylen Vanessa Ospina, Mariano Provencio
No abstract text is available yet for this article.
June 5, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37303221/cdh1-and-hereditary-diffuse-gastric-cancer-a-narrative-review
#24
JOURNAL ARTICLE
Stephanie N Gregory, Jeremy L Davis
BACKGROUND AND OBJECTIVE: Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that increases lifetime risk of diffuse-type gastric cancer which carries a dismal overall survival. Due to the high prevalence of cancer in patients with CDH1 variants, early screening and prophylactic total gastrectomy (PTG) are recommended. This review aims to summarize the current understanding of CDH1 and HDGC, highlighting its molecular and cellular implications as well as its clinical management and research efforts...
June 5, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37417292/epidemiology-staging-and-management-of-mucosal-melanoma-of-the-head-and-neck-a-narrative-review
#25
JOURNAL ARTICLE
Yu Jin Jeong, John F Thompson, Sydney Ch'ng
BACKGROUND AND OBJECTIVE: Mucosal melanoma of the head and neck (MMHN) are rare, aggressive neoplasms of melanocyte origin that remain incompletely understood and have a poor prognosis, with high rates of locoregional recurrence and distant metastasis. Several recent studies having expanded understanding of MMHN, we undertook a review of the latest evidence pertaining to its epidemiology, staging, and management. METHODS: A literature search was conducted for peer-reviewed articles reporting and discussing the epidemiology, staging, and management of MMHN...
June 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37417291/geographical-ethnic-and-genetic-differences-in-pancreatic-cancer-predisposition
#26
JOURNAL ARTICLE
Sherilyn Zi Hui Liew, Kwok Wing Ng, Nur Diana Binte Ishak, Suat Ying Lee, Zewen Zhang, Jianbang Chiang, Joanne Yuen Yie Ngeow
Pancreatic cancer remains a leading cause of cancer-related mortality worldwide. Treatment outcomes remain largely dismal despite significant medical advancements. This lends urgency to the need to understand its risk factors in order to guide early detection and improve outcomes. There are both modifiable and non-modifiable risk factors, the more established of such being that of age, smoking, obesity, diabetes mellitus (DM), alcohol and certain genetic predisposition syndromes with underlying germline mutations...
June 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37417290/focal-versus-whole-gland-salvage-brachytherapy-for-recurrent-prostate-cancer-in-the-prostate-specific-membrane-antigen-pet-era-a-narrative-review
#27
JOURNAL ARTICLE
Lauren M Andring, Bin S Teh, Edward Brian Butler, Andrew M Farach
BACKGROUND AND OBJECTIVE: Prostate cancer is the second most common cause of cancer in men worldwide. A significant proportion of patients will develop biochemical failure after definitive radiotherapy and an increasing number of local failures are now identifiable with prostate specific membrane antigen (PSMA) positron emission tomography and computerized tomography (PET/CT). Brachytherapy (BT) represents an excellent option for definitive local salvage treatment. Consensus guidelines for the delivery of salvage BT are heterogenous and limited...
June 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37417289/differences-in-clinical-outcomes-based-on-molecular-markers-in-glioblastoma-patients-treated-with-concurrent-tumor-treating-fields-and-chemoradiation-exploratory-analysis-of-the-spare-trial
#28
JOURNAL ARTICLE
Louis Cappelli, Mehak Majid Khan, Allison Kayne, Spencer Poiset, Ryan Miller, Ayesha Ali, Muneeb Niazi, Wenyin Shi, Iyad Alnahhas
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite enormous research efforts, GBM remains a deadly disease. The standard-of-care treatment for patients with newly diagnosed with GBM as per the National Cancer Comprehensive Cancer Network (NCCN) is maximal safe surgical resection followed by concurrent chemoradiation and maintenance temozolomide (TMZ) with adjuvant tumor treating fields (TTF). TTF is a non-pharmacological intervention that delivers low-intensity, intermediate frequency alternating electric fields that arrests cell proliferation by disrupting the mitotic spindle...
June 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37417288/lymph-node-staging-with-68ga-psma-pet-in-patients-with-intermediate-and-high-risk-prostate-cancer-suitable-for-radical-prostatectomy-managed-in-a-prostate-cancer-unit
#29
JOURNAL ARTICLE
Umberto Vittorio Maestroni, Davide Campobasso, Giulio Guarino, Anna Acampora, Maura Scarlattei, Francesco Ziglioli, Francesco Dinale, Giorgio Baldari, Silvia Migliari, Donatello Gasparro, Stefania Ferretti, Enrico Maria Silini, Livia Ruffini
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is coming up as a superior imaging tool for prostate cancer (PCa). However, its use in primary staging is still debated. The aim of this study was to assess accuracy of 68Ga-PSMA PET/CT in staging patients with intermediate and high risk PCa candidates to radical prostatectomy managed in the Prostate Cancer Unit of our institution. METHODS: We retrospectively evaluated patients with biopsy-proven PCa staged through PSMA PET/CT before undergoing radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND)...
June 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37303220/flot-or-cross-for-gastroesophageal-junction-cancers%C3%A3-%C3%A2-is-the-debate-over-yet
#30
JOURNAL ARTICLE
Bushra Shariff, Rutika Mehta
In the last two decades, the incidence of gastroesophageal junction (GEJ) adenocarcinomas (AC) has increased, in part due to the increasing prevalence of obesity and untreated gastroesophageal reflux disease (GERD). Esophageal and GEJ cancers have become one of the leading causes of cancer deaths worldwide due to its aggressive nature. While the mainstay of treatment for locally advanced gastroesophageal cancers (GECs) remains surgery, several studies have now shown that multimodality approach yields better outcomes...
May 25, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37211774/the-future-is-here%C3%A3-%C3%A2-targeted-therapies-are-coming-of-age-in-biliary-tract-cancers
#31
EDITORIAL
Daniel Neureiter, Matthias Ocker
No abstract text is available yet for this article.
May 15, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37211773/comparison-of-parpi-efficacy-according-to-homologous-recombination-deficiency-biomarkers-in-patients-with-ovarian-cancer-a-systematic-review-and-meta-analysis
#32
JOURNAL ARTICLE
Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J Ernst, Lida A Mina
BACKGROUND: Mutations in the BRCA1/2 (BRCA) genes are associated with response to poly(ADPribose) polymerase (PARP) inhibitors (PARPi). In addition, there are different homologous recombination deficiency (HRD) biomarkers available in clinical practice [e.g., genome-wide loss-of-heterozygosity (gLOH) and myChoice® score] that identify patients who can benefit from PARPi. Inconsistencies in biomarkers used in PARPi clinical trials make it challenging to identify clinically relevant predictive biomarkers...
May 15, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37164933/overview-of-late-complications-of-radiation-therapy-in-uveal-melanoma
#33
JOURNAL ARTICLE
Andrew J Wong, Amy C Schefler, Bin S Teh
No abstract text is available yet for this article.
May 9, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37164932/re-orient-ing-antitumor-immunity-in-egfr-mutant-non-small-cell-lung-cancer-are-antiangiogenics-the-key
#34
JOURNAL ARTICLE
Aaron J Franke, Erin L Schenk
No abstract text is available yet for this article.
April 25, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37081710/image-guided-percutaneous-locoregional-therapies-for-hepatocellular-carcinoma
#35
JOURNAL ARTICLE
Olivier Chevallier, Ken Zhao, Brett Marinelli, Hooman Yarmohammadi
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the 3rd leading cause of cancer death worldwide. Treatment options include surgical resection, liver transplantation, imageguided percutaneous locoregional options, external beam radiation therapy (EBRT) and systemic therapies. Treatment choice depends on the stage of the disease and patient's characteristics including performance status and liver function. Barcelona Clinic Liver Cancer (BCLC) staging system, with its recent 2022 update, is one of the most widely endorsed staging system...
April 18, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37081709/single-cell-sequencing-of-neutrophils-demonstrates-phenotypic-heterogeneity-and-functional-plasticity-in-health-disease-and-cancer
#36
JOURNAL ARTICLE
Alistair S McLaren, Rana Fetit, Colin S Wood, John Falconer, Colin W Steele
A vital constituent of innate immunity, neutrophils had previously been considered functionally rigid with a fixed, defined role in host pathogen response, in part due to their fleeting lifespan. However, that consensus opinion has changed with evidence of functional neutrophil plasticity in a range of diseases including cancer. Typically difficult to sequence due to their low level of transcriptomic activity, advances in single cell RNA sequencing has allowed for closer examination of the neutrophil transcriptome in humans and mouse models and their interaction with other immune system constituents, both in health and disease, allowing for description of neutrophil phenotypes beyond previous descriptions reliant upon microscopic appearance, surface marker expression, and function...
April 12, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37038056/rezvilutamide-yet-another-androgen-receptor-pathway-inhibitor-for-metastatic-hormone-sensitive-prostate-cancer
#37
JOURNAL ARTICLE
Jeanny B Aragon-Ching
No abstract text is available yet for this article.
April 7, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37160670/the-emerging-role-for-car-t-cells-in-solid-tumor-oncology
#38
REVIEW
Sebastian Klobuch, Tom T P Seijkens, John B A G Haanen
In recent years, treatment with chimeric antigen receptor (CAR) T-cells has revolutionized the outcomes of patients with relapsed or refractory hematological malignancies with long-term remissions in >30% of patients. Similarly, the introduction of immune checkpoint inhibitor therapy changed the therapeutic landscape for several solid malignancies also leading to impressive long-term remission in patients. However, so far CAR T-cell therapy in solid tumors has shown low response rates and especially a lack of long-term remissions...
April 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37038055/therapeutic-approaches-in-intermediate-stage-hepatocellular-carcinoma-hcc-a-novel-insight-of-adjuvant-transarterial-chemoembolization-tace
#39
JOURNAL ARTICLE
Paula Fernández-Palanca, José L Mauriz
No abstract text is available yet for this article.
March 30, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37038054/management-of-locally-advanced-intrahepatic-cholangiocarcinoma-a-narrative-review
#40
JOURNAL ARTICLE
Luke Bressler, Natalie Bath, Ashish Manne, Eric Miller, Jordan M Cloyd
BACKGROUND AND OBJECTIVE: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary hepatic malignancy, which has increased in incidence over the past decades. While surgical resection is the standard of care for patients with early-staged disease, many patients present with locally advanced and unresectable tumors. Given the importance of locoregional control and the potential for downstaging to resectability, knowledge of advances in the management of locally advanced ICC is critical for optimizing outcomes...
March 30, 2023: Chinese Clinical Oncology
journal
journal
47887
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.